1. Home
  2. CSBR vs MNOV Comparison

CSBR vs MNOV Comparison

Compare CSBR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

HOLD

Current Price

$5.89

Market Cap

81.0M

Sector

Health Care

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.43

Market Cap

69.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSBR
MNOV
Founded
1985
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
69.4M
IPO Year
2015
2004

Fundamental Metrics

Financial Performance
Metric
CSBR
MNOV
Price
$5.89
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
4.4K
71.3K
Earning Date
03-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
161.11
N/A
EPS
N/A
N/A
Revenue
$2,900,000.00
$2,360,807.00
Revenue This Year
$4.84
N/A
Revenue Next Year
$11.51
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$5.50
$1.17
52 Week High
$9.63
$1.96

Technical Indicators

Market Signals
Indicator
CSBR
MNOV
Relative Strength Index (RSI) 45.13 62.00
Support Level N/A $1.38
Resistance Level $6.31 $1.51
Average True Range (ATR) 0.43 0.07
MACD -0.06 0.02
Stochastic Oscillator 10.49 61.85

Price Performance

Historical Comparison
CSBR
MNOV

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: